- Home
- AITR vs ELTX Comparison
AITR vs ELTX Comparison
Compare AITR & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AITR
- ELTX
- Stock Information
- Founded
- AITR 2022
- ELTX 2011
- Country
- AITR United States
- ELTX United States
- Employees
- AITR N/A
- ELTX N/A
- Industry
- AITR
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- AITR
- ELTX Health Care
- Exchange
- AITR Nasdaq
- ELTX Nasdaq
- Market Cap
- AITR 82.6M
- ELTX 49.7M
- IPO Year
- AITR 2023
- ELTX 2021
- Fundamental
- Price
- AITR $10.54
- ELTX $4.16
- Analyst Decision
- AITR
- ELTX Buy
- Analyst Count
- AITR 0
- ELTX 2
- Target Price
- AITR N/A
- ELTX $10.00
- AVG Volume (30 Days)
- AITR 71.3K
- ELTX 16.1K
- Earning Date
- AITR 01-01-0001
- ELTX 11-07-2024
- Dividend Yield
- AITR N/A
- ELTX N/A
- EPS Growth
- AITR N/A
- ELTX N/A
- EPS
- AITR N/A
- ELTX N/A
- Revenue
- AITR N/A
- ELTX N/A
- Revenue This Year
- AITR N/A
- ELTX N/A
- Revenue Next Year
- AITR N/A
- ELTX N/A
- P/E Ratio
- AITR N/A
- ELTX N/A
- Revenue Growth
- AITR N/A
- ELTX N/A
- 52 Week Low
- AITR $10.11
- ELTX $2.96
- 52 Week High
- AITR $10.57
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- AITR 78.43
- ELTX 40.82
- Support Level
- AITR $10.51
- ELTX $4.05
- Resistance Level
- AITR $10.57
- ELTX $4.89
- Average True Range (ATR)
- AITR 0.01
- ELTX 0.28
- MACD
- AITR -0.00
- ELTX -0.06
- Stochastic Oscillator
- AITR 83.33
- ELTX 27.37
About AITR AI TRANSPORTATION ACQUISITION CORP Ordinary shares
AI Transportation Acquisition Corp is a blank check company.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.